1. Home
  2. MITQ vs SHPH Comparison

MITQ vs SHPH Comparison

Compare MITQ & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.58

Market Cap

5.9M

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.84

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
SHPH
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.2M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
MITQ
SHPH
Price
$0.58
$0.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
481.0K
168.0K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$20,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$63.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.12
52 Week High
$1.66
$5.59

Technical Indicators

Market Signals
Indicator
MITQ
SHPH
Relative Strength Index (RSI) 46.41 41.35
Support Level $0.49 $0.58
Resistance Level $0.64 $1.13
Average True Range (ATR) 0.08 0.15
MACD 0.00 0.01
Stochastic Oscillator 21.45 17.88

Price Performance

Historical Comparison
MITQ
SHPH

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: